While all these candidate molecules warrant further investigation across further cohorts, together these data suggest that the measurement of the blood immune protein response to PMA/ionomycin stimulation may hold promise as a predictive tool for subsequent risk for infection in CLL patients on targeted BTK inhibitor immune therapies, such as ibrutinib. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.